Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): Implications for autoantigen modification during pathogenesis

Clinical and Experimental Immunology

Volumn 130, Issue 1, 2002, Pages 131-139

  Al Bukhari, T A M A ^a,e   Radford, P M ^a   Bouras, G ^a   Davenport, C ^a   Trigwell, S M ^a   Bottazzo, G F ^b   Lai, M ^a,f   Schwartz, H L ^c,g   Tighe, P J ^a   Todd, I ^a,d  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e UMM AL QURA UNIVERSITY   (Saudi Arabia)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g GENENTECH INC   (United States)

Author keywords

Autoimmune polyendocrine syndrome type II; GAD 65; Linear epitopes; Phage peptide display libraries; Stiff man syndrome

Indexed keywords

AUTOANTIGEN; EPITOPE; GLUTAMATE DECARBOXYLASE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN SECONDARY STRUCTURE; RAT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; GLUTAMATE DECARBOXYLASE; HUMANS; ISOENZYMES; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; POLYENDOCRINOPATHIES, AUTOIMMUNE; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RANDOM ALLOCATION; STIFF-PERSON SYNDROME;

EID: 18544380972     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01960.x     Document Type: Article

References (30)

1. Leslie RDG, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in type 1 (insulin-dependent) diabetes. Diabetologia 1999; 42:3-14.
2. Kanaani J, Lissin D, Kash SF, Baekkeskov S. The hydrophilic isoform of glutamate decarboxylase, GAD67, is targeted to membranes and nerve terminals independent of dimerization with the hydrophilic membrane-anchored isoform, GAD65. J Biol Chem 1999; 274:37200-9.
3. Bonifacio E, Lampasona V, Bernasconi L, Ziegler A-G. Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. Diabetes 2000; 49:202-8.
4. Solimena M, Folli F, Denis-Donini S. Autoantibodies to glutamate decarboxylase in a patient with stiff man syndrome, epilepsy and type 1 diabetes mellitus. N Engl J Med 1988; 318:1012-20.
5. Baekkeskov S, Aanstoot HJ, Christgau S et al. Identification of the 64k autoantigen in insulin-dependent diabetes as the GABA synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347:151-6.
6. Christie MR, Genovese S, Cassidy D et al. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994; 43:1254-9.
7. Sohnlein P, Muller M, Syren K, The Childhood Diabetes in Finland Study Group, Richter W. Epitope spreading and a varying but not disease-specific GAD65 antibody response in type 1 diabetes. Diabetologia 2000; 43:210-7.
8. Falorni A, Ackefors M, Carlberg C et al. Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM. Diabetologia 1996; 39:1091-1098.
9. Daw K, Powers AC. Two distinct glutamic acid decarboxylase autoantibody specificities in IDDM target different epitopes. Diabetes 1995; 44:216-20.
10. Butler MH, Solimena M, Dirkx R Jr, Hayday A, De Camilli P. Identification of a dominant epitope of glutamic acid decarboxylase (GAD65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993; 178:2097-106.
11. 65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 1994; 180:595-606.
12. Li L, Hagopian WA, Brashear HR, Daniels T, Lernmark A. Identification of autoantibody epitopes of glutamic acid decarboxylase in stiff-man syndrome patients. J Immunol 1994; 152:930-4.
13. Daw K, Ujihara N, Atkinson M, Powers AC. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 1996; 156:818-25.
14. Mauch L, Abney CC, Berg H, Scherbaum WA, Liedvogel B, Northemann W. Characterization of a linear epitopes within the human pancreatic 64-kDa glutamic acid deacarboxylase and its autoimmune recognition by sera from insulin-dependent diabetes mellitus patients. Eur J Biochem 1993; 212:597-603.
15. Rharbaoui F, Granier C, Kellou M et al. Peptide specificity of high-titer anti-glutamic acid decarboxylase (GAD) 65 autoantibodies. Immunol Lett 1998; 62:123-30.
16. Ziegler B, Strebelow M, Rjasanowski I, Schlosser M, Ziegler M. A monoclonal antibody-based characterization of autoantibodies against glutamic acid decarboxylase in adults with latent autoimmune diabetes. Autoimmunity 1998; 28:61-8.
17. Davenport C, Radford PM, Al-bukhari TAMA, Lai M, Bottazzo G-F, Todd I. Heterogeneity in the occurrence of a subset of autoantibodies to glutamic acid decarboxylase in autoimmune polyendocrine patients with islet cell antibodies. Clin Exp Immunol 1998; 111:497-505.
18. Bjork E, Velloso LA, Kampe O, Karlsson FA. GAD-autoantibodies in insulin-dependent diabetes mellitus, stiff-man syndrome and autoimmune polyendocrine syndrome type I recognise different epitopes. Diabetes 1994; 43:161-5.
19. Schwartz HL, Chandonia J-M, Kash SF et al. High-resolution autoreactive epitope mapping and structural modelling of the 65 kDa form of human glutamic acid decarboxylase. J Mol Biol 1999; 287:983-99.
20. Richter W, Shi Y, Baekkeskov S. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Proc Natl Acad Sci USA 1993; 90:2832-6.
21. Syren K, Lindsay L, Stoehrer B et al. Immune reactivitiy of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase. J Immunol 1996; 157:5208-14.
22. Powers AC, Bavik K, Tremble J, Daw K, Scherbaum WA, Banga JP. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders. Clin Exp Immunol 1999; 118:349-56.
23. Myers MA, Davies JM, Tong JC et al. Conformational epitopes on the diabetes autoantigen GAD65 identified by peptide phage display and molecular modelling. J Immunol 2000; 165:3830-8.
24. Chang Y, Gottlieb D. Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylase. J Neurosci 1988; 8:2123-30.
25. Ujihara N, Daw K, Gianani R, Boel E, Yu L, Powers AC. Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type 1 diabetes. Diabetes 1994; 43:968-75.
26. Ziegler B, Augstein P, Luhder F et al. Monoclonal antibodies specific to the glutamic acid decarboxylase 65 kDa isoform derived from a non-obese diabetic (NOD) mouse. Diabetes Res 1994; 25:47-64.
27. Ziegler B, Augstein P, Schroder D et al. Glutamate decarboxylase (GAD) is not detectable on the surface of rat islet cells examined by cytofluorometry and complement-dependent antibody-mediated cytotoxicity of monoclonal GAD antibodies. Horm Metab Res 1996; 28:11-5.
28. Davenport C, Lovell H, James RFL, Todd I. Brain-reactive autoantibodies in BB/d rats do not recognize glutamic acid decarboxylase. Clin Exp Immunol 1995; 101:127-35.
29. Schmidli RS, Colman PG, Bonifacio E. Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAB Workshop. Diabetes 1995; 44:636-40.
30. Trigwell SM, Radford PM, Page SR et al. Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus. Clin Exp Immunol 2001; 126:242-9.